BiomedReports: News and FDA Updates for Senomyx (Nasdaq:SNMX), Abraxis (NASDAQ:ABII), Human Genome Scs. (Nasdaq:HGSI), Caraco (N

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com

On 03/08/09, Senomyx, Inc. (Nasdaq:SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, and Firmenich SA, the world's largest privately-owned fragrance and flavor company, announced they have entered into a collaborative research, development, commercialization and license agreement for Senomyx's novel flavor ingredients intended to enhance the taste of sucrose (table sugar), fructose, andRebaudioside (stevia).

On 03/08/09, Abraxis BioScience, Inc. (NASDAQ: ABII | Quote | Chart | News | PowerRating), an integrated, global biotechnology firm, reported the results of a phase 2 study were presented at the 13th Annual World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC) in San Francisco, CA. The data presented provided evidence of anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC) receiving first- line treatment regimens of albumin-bound nab-paclitaxel (ABRAXANE for Injectable Suspension) in combination with carboplatin.

On 03/08/09, Human Genome Sciences, Inc. (Nasdaq: HGSI | Quote | Chart | News | PowerRating) announced the closing of its public offering of 26,697,250 newly issued shares of its common stock at a price to the public of $14.00 per share, which includes 3,482,250 shares sold upon exercise by the underwriters of their option to purchase additional shares.The net proceeds to the Company from the offering are approximately $356.7 million, after deducting the underwriting discount and estimated offering expenses.

On 03/08/09, Caraco Pharmaceutical Laboratories, Ltd. (NYSE: CPD | Quote | Chart | News | PowerRating) announces it has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol(R).

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

CONTACT: Mike Havrilla, Managing Editor, BiomedReports.Com
e-mail: mike@biomedreports.com
Tel: +1 323 472 4480
Fax: +1 888 210 3556

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Abraxis Bioscience Inc. (ABII) ABII. Abraxis Bioscience Inc. (ABII) has Short Term PowerRatings at TradingMarkets. Details on Abraxis Bioscience Inc. (ABII) Short Term PowerRatings is available at This Link.

For full details on Senomyx Inc (SNMX) SNMX. Senomyx Inc (SNMX) has Short Term PowerRatings at TradingMarkets. Details on Senomyx Inc (SNMX) Short Term PowerRatings is available at This Link.

For full details on Human Genome Sciences (HGSI) HGSI. Human Genome Sciences (HGSI) has Short Term PowerRatings at TradingMarkets. Details on Human Genome Sciences (HGSI) Short Term PowerRatings is available at This Link.

For full details on Caraco Pharm Labs (CPD) CPD. Caraco Pharm Labs (CPD) has Short Term PowerRatings at TradingMarkets. Details on Caraco Pharm Labs (CPD) Short Term PowerRatings is available at This Link.